Page 5 - போட்டி முறையீடு தீர்ப்பாயம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Pfizer, Flynn accused of charging the NHS unfairly high prices for anti-epilepsy drug

Pfizer, Flynn accused of charging the NHS unfairly high prices for anti-epilepsy drug
pharmatimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmatimes.com Daily Mail and Mail on Sunday newspapers.

United kingdomAndrea coscelliUnited kingdom competitionMarkets authorityCompetition appeal tribunalஒன்றுபட்டது கிஂக்டம்ஒன்றுபட்டது கிஂக்டம் போட்டிசந்தைகள் அதிகாரம்போட்டி முறையீடு தீர்ப்பாயம்

Pfizer And Flynn Accused Of Illegal Pricing In U K For Vital Anti-epilepsy Drugs

Pfizer And Flynn Accused Of Illegal Pricing In U.K For Vital Anti-epilepsy Drugs NEW YORK CITY (dpa-AFX) - The UK s Competition and Markets Authority or CMA has provisionally found that Pfizer and Flynn abused their dominant positions to overcharge the U.K. s National Health Service or NHS for vital anti-epilepsy drugs, after reassessing the case. The CMA has provisionally found that the companies exploited a loophole by de-branding the drug - known as Epanutin prior to September 2012 - with the effect that the drug was not subject to price regulation in the way branded drugs are. As Pfizer and Flynn were the dominant suppliers of the drug in the UK, the NHS had no choice but to pay unfairly high prices for the vital medicine.

United kingdomUk national health serviceMarkets authorityHealth serviceCompetition appeal tribunalஒன்றுபட்டது கிஂக்டம்இங்கிலாந்து தேசிய ஆரோக்கியம் சேவைசந்தைகள் அதிகாரம்ஆரோக்கியம் சேவைபோட்டி முறையீடு தீர்ப்பாயம்

CMA accuses pharma firms Pfizer and Flynn of charging NHS illegal prices for anti-epilepsy drug

CMA accuses pharma firms Pfizer and Flynn of charging NHS illegal prices for anti-epilepsy drug whatsapp Pfizer and Flynn abused their dominant positions and charged the NHS unfairly high prices for life-saving phenytoin sodium capsules, for which they were the dominant suppliers to the UK, the CMA has found. The UK’s competition watchdog has accused pharmaceutical firms Pfizer and Flynn of breaking competition law and overcharging the NHS for crucial anti-epilepsy drugs, in a new re-investigation following a years-long battle with the companies. Pfizer and Flynn “abused their dominant positions” and charged the NHS “unfairly high prices” for life-saving phenytoin sodium capsules, for which they were the dominant suppliers to the UK, the CMA has found in a new investigation five years after it first fined the companies.

United kingdomAndrea coscelliCompetition appeal tribunalChief executiveஒன்றுபட்டது கிஂக்டம்போட்டி முறையீடு தீர்ப்பாயம்தலைமை நிர்வாகி

Pfizer epilepsy drug prices were unfairly high, UK review finds

Message : Required fields (Reuters) -Britain s competition watchdog is sticking with its view that Pfizer and Flynn Pharma broke the law by charging Britain s public health service unfairly high prices for an epilepsy drug, after being asked to reassess a record fine. The drugmakers made use of a loophole so that the capsules, branded Epanutin prior to September 2012, were not subject to price regulation for branded drugs, the Competition and Markets Authority (CMA) found in its provisional review https://www.gov.uk/government/news/cma-accuses-pharma-firms-of-illegal-pricing. In 2016, the CMA fined https://www.reuters.com/article/us-pfizer-britain-fine-idUSKBN13W0VT Pfizer and Flynn a record 90 million pounds ($125 million) for the price hike. However, the companies in 2018 won an appeal https://www.reuters.com/article/uk-pfizer-britain-fine-idUKKCN1J327D against the penalty, and the Competition Appeal Tribunal referred the matter back to the CMA.

United kingdomMark potterPushkala aripakaBritain national health serviceMarkets authorityCompetition appeal tribunalNational health serviceBengaluru editingRashmi aichஒன்றுபட்டது கிஂக்டம்குறி பாடர்பிரிட்டன் தேசிய ஆரோக்கியம் சேவைசந்தைகள் அதிகாரம்போட்டி முறையீடு தீர்ப்பாயம்தேசிய ஆரோக்கியம் சேவைபெங்களூரு திருத்துதல்

Pfizer Inc accused of abusing market position to overcharge NHS with 1,600% price hikes

Pfizer Inc accused of abusing market position to overcharge NHS with 1,600% price hikes
proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.

United kingdomFlynn pharmaAndrea coscelliNational health serviceMarkets authorityCompetition appeal tribunalஒன்றுபட்டது கிஂக்டம்ஃப்லிந் பார்மாதேசிய ஆரோக்கியம் சேவைசந்தைகள் அதிகாரம்போட்டி முறையீடு தீர்ப்பாயம்